Metabolic Syndrome Status Research Articles

Transitions in metabolic syndrome and metabolic obesity status over time and risk of urologic cancer: A prospective cohort study.

The effects of metabolic obesity (MO) phenotypes status and their dynamic changes on urologic cancer (UC) is ignored. We aimed to investigate the association between metabolic syndrome (MetS) and MO status at baseline, their dynamic changes and UC risk. This paper studied 97,897 subjects who were free of cancers at baseline (2006-2007). Individuals were classified into four MO phenotypes by MetS and obesity at baseline. Transitions in MetS and MO status from 2006-2007 to 2008-2009 were considered. The hazard ratios (HRs) and 95% confidence intervals (CIs) for UC were assessed by multifactorial Cox proportional risk regression models. The main limitations of this study are as follows: the ratio of men to women in the cohort is unbalanced; the impacts of MetS and MO on each cancer type (kidney cancer, prostate cancer, bladder cancer) have not been analyzed separately; the transition intervals of MetS and MO phenotypes are relatively short. From baseline (2006-2007) survey to December 31, 2020, during a median follow-up of 14.02 years, 554 cases of UC were diagnosed. Participants with MetS [HRs (95% CI) = 1.26 (1.06-1.49)] and metabolically unhealthy obesity (MUO) [HRs (95% CI) = 1.49 (1.17-1.89)] had significantly higher risk of UC than those with non-MetS and metabolically healthy normal weight (MHN). Transitions in MetS and MO phenotypes over time were studied. Compared with non-MetS to non-MetS, the risks for UC in MetS to MetS [HRs (95% CI) = 1.45 (1.11-1.88)] was increased. Compared with MHN to MHN, both MUO to metabolically healthy obesity (MHO) [HRs (95% CI) = 2.65 (1.43-4.92)] and MUO to MUO [HRs (95% CI) = 1.60 (1.06-2.42)] had significantly higher UC risk. MetS and MUO increased the UC risk at baseline. Transitions of MetS to MetS, MUO to MUO and even MUO to MHO over time significantly increased the risk of UC development.

Systematic characterization and efficient prediction of cobalamin C deficiency clinical phenotypes using network analysis and deep learning on multi-omics data

As a monogenic disease, cobalamin C (cblC) deficiency lacks a clear correlation between gene pathogenic mutations and its spectrum of disease phenotypes, necessitating the understanding of molecular mechanisms how diverse clinical phenotypes emerge. This work aimed to disentangle the phenotypic complexity of cblC deficiency via network analysis and deep learning on multi-omics (proteomics and metabolomics) data. For this purpose, a novel computational framework was developed to systematically characterize and efficiently predict clinical phenotypes of cblC deficiency utilizing a Connect the Dots (CTD)-based Hybrid data Structural Representation of each patient and graph convolutional network (GCN)-based Multi-Omics Learning (CTDHSR-GCNMOL). CTD algorithm enabled the identification of relevant perturbed proteins or metabolites and the construction of clinical phenotype-specific co-perturbation network. GCN allowed efficient learning of subtle change patterns across clinical phenotypes not only depending on the hybrid feature description (Euclidean structure hybridized with non-Euclidean structure) of each patient but on the interaction exploration between patients offered by sample similarity network. Investigated by three clinical phenotypes (epilepsy, developmental delay and metabolic syndrome), the results showed that CTDHSR-GCNMOL identified the subsets of perturbed proteins or metabolites highly specific to each clinical phenotype and established each main disease module (network) for systematic characterization. For proteomics, epilepsy was characterized by the dysregulation of reported TAGLN2, SH3BGRL3 and LTA4H, and developmental delay was characterized by the dysregulation of reported HSP90AB1, PRDX1, GDI2, VIM, PNP and BLVRA with high confidence (selection frequencies). For untargeted metabolomics in negative ion mode, the disease status of metabolic syndrome could be well interpreted by the disturbed pathways of the top-ranked 20 perturbed metabolites all of which have been reported to be closely related with its pathogenesis in previous studies. These disturbed pathways involved butanoate metabolism, purine metabolism, alanine, aspartate and glutamate metabolism, pyrimidine metabolism, fructose and mannose metabolism, galactose metabolism, amino sugar and nucleotide sugar metabolism, and steroid hormone biosynthesis. Based on the hybridization of the abundances of perturbed proteins and metabolites with the topological structures of patient-specific perturbation network, CTDHSR-GCNMOL yielded desired prediction performance across three clinical phenotypes and outperformed the traditional block PLSDA. All these findings verified the effectiveness of CTDHSR-GCNMOL in gaining useful insights into the phenotypic complexity of cblC deficiency and guiding its targeted treatment strategies.

The association of the comorbidity status of metabolic syndrome and cognitive dysfunction with health-related quality of life.

Both metabolic syndrome (MetS) and cognitive dysfunction impair health-related quality of life (HRQOL). This study aims to determine whether individuals experiencing both MetS and cognitive dysfunction have lower HRQOL. This cross-sectional study enrolled 567 participants who attended outpatient clinics at a medical center in northern Taiwan. MetS was diagnosed according to the modified criteria for the Asian population. Cognitive function was categorized as normal, mild cognitive dysfunction, and advanced cognitive dysfunction according to the score of the Montreal Cognitive Assessment, Taiwanese version. HRQOL was assessed using the SF-36v2® Health Survey (SF-36v2). The associations of the comorbidity status of MetS and cognitive dysfunction with HRQOL were analyzed using linear regression models, adjusting for age, sex, marital status, education level, income groups, and activities of daily living. Out of 567 participants, 33 (5.8%) had MetS with mild cognitive dysfunction, and 34 (6.0%) had MetS with advanced cognitive dysfunction. Participants with both MetS and advanced cognitive dysfunction exhibited the lowest scores in the physical component summary and almost all scales of HRQOL. MetS exacerbated the inverse association between mild cognitive dysfunction and the mental component summary. For those with MetS, the scores on scales of role physical, bodily pain, vitality, and social functioning worsened as cognitive function deteriorated (all Ptrend<0.05). As the severity of comorbidity between MetS and cognitive dysfunction varies, patients exhibited poorer performance in different aspects of HRQOL. Future research is needed to find solutions to improve HRQOL for patients with both MetS and cognitive dysfunction.

Association of sleep timing, sleep duration, and sleep latency with metabolic syndrome in middle-aged adults in Korea: A cross-sectional and longitudinal study

ObjectiveSleep is a potential risk factor for metabolic syndrome. We investigated the associations of various sleep characteristics with the status and incidence of metabolic syndrome in middle-aged Koreans. MethodsUsing data from a community-based Korean Medicine Daejeon Citizen Cohort study on participants aged 30-50years, cross-sectional (n = 1984) and longitudinal (n = 1216, median follow-up: 2.1years) analyses were performed. To study the association of metabolic syndrome and five components with various sleep characteristics, measured using the Pittsburgh Sleep Quality Index, we used Poisson and logistic regression and Cox proportional hazard regression analyses, adjusting for covariates. ResultsOf 1984 participants, 66%, 19%, and 15% belonged to the non-metabolic syndrome, pre-metabolic syndrome, and metabolic syndrome groups, respectively. After covariate adjustments, the pre-metabolic syndrome group was associated with late mid-sleep time (≥5:00; prevalence ratios 1.61, 95% confidence interval 1.01-2.54) and late bedtime (≥2:00; prevalence ratios 1.55, 95% confidence interval 1.03-2.34), and the metabolic syndrome group was associated with long sleep latency (prevalence ratios 1.33, 95% confidence interval 1.03-1.73), poor sleep quality (prevalence ratios 1.38, 95% confidence interval 1.07-1.78), and early wake time (<6:00; prevalence ratios 1.29, 95% confidence interval 1.01-1.63). Longitudinal analysis of participants without metabolic syndrome at baseline indicated a significant increase in metabolic syndrome risk associated with very short sleep duration (<6 hours; hazard ratio 1.72, 95% confidence interval 1.06-2.79), long sleep latency (>30 minutes; hazard ratio 1.86, 95% confidence interval 1.1-3.12), and early wake time (<6:00 o’clock; hazard ratio 1.73, 95% confidence interval 1.01-2.97). ConclusionSleep characteristics, such as short duration, long latency, and early wake time, were associated with an increased risk of metabolic syndrome in middle-aged adults.

Associations between Anemia and Glomerular Filtration Rate and Albuminuria in Korean Adults by Metabolic Syndrome Status: Analysis of KNHNES V-3 Data

Associations between Anemia and Glomerular Filtration Rate and Albuminuria in Korean Adults by Metabolic Syndrome Status: Analysis of KNHNES V-3 Data

Impact of Sleeve Gastrectomy on Uric Acid Levels in Patients with Obesity: A Comparative Study.

This study aimed to investigate the incidence of hyperuricemia in obese individuals with or without metabolic syndrome and assess the impact of sleeve gastrectomy surgery on the amelioration of hyperuricemia and metabolic syndrome. A prospective study was conducted on patients with obesity who were candidates for laparoscopic sleeve gastrectomy. These patients were diligently followed for 1year after the surgical procedure. The assessment of hyperuricemia and metabolic syndrome was carried out both before and one year after the surgery. A total of 198 patients (30 males and 168 females) underwent sleeve gastrectomy. After 1year, there was a notable decline in the prevalence of hyperuricemia, decreasing from 77 to 36 cases (a reduction of 46.75%) among females and from 18 to 8 cases (a reduction of 44.44%) among males. Prior to the surgery, 60.6% of patients (120 out of 198) were diagnosed with metabolic syndrome, and 36.7% of these patients exhibited improvements in their metabolic syndrome status. Among individuals with metabolic syndrome, significant enhancements were observed in various anthropometric and laboratory measurements, including reductions in hypertriglyceridemia, hyperuricemia, and hypercholesteremia. A logistic regression analysis revealed that in females, changes in creatinine, glomerular filtration rate (GFR), weight loss, body mass index (BMI), and triglyceride reduction all had a notable impact on the likelihood of recovering from hyperuricemia. These findings underscore the clinical relevance of this surgical intervention in managing obesity-related conditions.

Metabolic Syndrome Status Changes and Cognitive Functioning: Insights from the Lifelines Cohort Study

BackgroundMetabolic syndrome is associated with increased risk of dementia. Yet, findings on how longitudinal development of metabolic syndrome status affects cognition remain controversial.ObjectivesThis study examines whether individuals with different changes in metabolic syndrome status differ in cognitive functioning. Additionally, the prevalence of metabolic syndrome within the Lifelines population-based study is investigated.Design14609 Lifelines participants (mean age 60.8, 56.4% women) were divided into four groups based on their metabolic syndrome status changes between 2007–2013 (1) and between 2014–2017 (2): without metabolic syndrome (N=10863; absent at 1 and 2), de novo metabolic syndrome (N=1340; absent at 1 and present at 2), remitting metabolic syndrome (N=825; present at 1 and absent at 2), and persistent metabolic syndrome (N=1581; present at 1 and 2). ANCOVA models were employed to assess group differences in psychomotor function, visual attention, visual learning, and working memory assessed using the Cogstate Brief Battery.ResultsAccounting for education, age, sex, and time between examinations, groups did not statistically differ in any of the four cognitive outcomes. The prevalence of metabolic syndrome within the Lifelines population increased with age and differed among men and women.ConclusionPerformance in psychomotor function, visual attention, visual learning, and working memory measured by the Cogstate Brief Battery did not differ between individuals with different changes in metabolic syndrome. The length of metabolic syndrome exposure was unknown, making our results exploratory and calling for future studies addressing this gap.

Prevalence of impaired renal function among childless men as compared to fathers: a population-based study

Male reproductive impairment has been linked with an increased risk of numerous non-communicable diseases. Yet, epidemiological data on renal disease among subfertile men is scarce. Therefore, by using male childlessness as a proxy for male infertility, we aimed to investigate its association with renal function. Data was sourced from a population-based cohort including 22,444 men. After exclusion of men aged < 45 years (n = 10,842), the remaining men were divided into two groups: these being childless (n = 5494) and fathers (n = 6108). Logistic regression was applied to explore the association between male childlessness and renal impairment. Childless men as compared to fathers, were more likely to have an estimated-glomerular filtration rate < 60 ml/min/1.73m2 (OR 1.36, 95 CI 1.08–1.70; p = 0.008). After adjustment for age, marital status, smoking habits, diabetes, hypertension and other components of metabolic syndrome, childless men were also more likely to have dipstick proteinuria (OR 1.85, 95 CI 1.16–2.95; p = 0.01). With the growing panorama of disease associated with male reproductive impairment, men with fertility issues may constitute a target population with potential benefit from closer follow-up of their renal function.

RELATIONSHIP OF PUPIL SIZE WITH REFRACTIVE ERROR IN METABOLIC SYNDROME AND NON METABOLIC SYNDROME: AMONG RURAL POPULATION IN MALANG

Introduction &amp; ObjectivesNearly one in four Indonesians has metabolic syndrome (MS). One of the microvascular side effectsin Metabolic Syndrome affects the eyes. The aim of this study to evaluate the relationship of pupilsize with refractive error in MS and non-MS groups among rural populations in Malang.&#x0D; MethodsA descriptive study was carried out in 2019 in three villages in Malang districts. A detailed ocularexamination was conducted on all participants who attended a research facility. We definedpupillary abnormalities and clinically important refractive errors. Blood samples were obtained todetermine the parameter of the metabolic syndrome by IDF 2006 criteria. Subjects were classifiedinto 2 groups: Metabolic Syndrome status and non metabolic syndrome.&#x0D; Results953 participants completed the examination which consists of 944 right eyes and 942 left eyes. Theresults of visual acuity on the right eye: emmetropia in 434 eyes, myopia with 252 eyes, hyperopiawith 141 eyes, and astigmatism with 17 eyes where if it is not significant if associated with pupillaryabnormalities (P-value 0.893). On the left eye, the emmetropia results were 444 eyes, while formyopia were 244 eyes, hyperopia as many as 138, and astigmatism in 116 eyes and if associatedwith pupillary abnormalities, the result also not significant (P-value 0.864). The result of pupil sizewith metabolic syndrome 499 eye and non syndrome metabolic 454 eye are not significant (p-value0.649).&#x0D; ConclusionRefractive error didn’t relate pupil size in metabolic syndrome and non metabolic syndrome.

Reduction of prevalence of patients meeting the criteria for metabolic syndrome with tirzepatide: a post hoc analysis from the SURPASS Clinical Trial Program

BackgroundMetabolic syndrome is characterized as the co-occurrence of interrelated cardiovascular risk factors, including insulin resistance, hyperinsulinemia, abdominal obesity, dyslipidemia and hypertension. Once weekly tirzepatide is approved in the US and EU for the treatment of type 2 diabetes (T2D) and obesity. In the SURPASS clinical trial program for T2D, tirzepatide demonstrated greater improvements in glycemic control, body weight reduction and other cardiometabolic risk factors versus placebo, subcutaneous semaglutide 1 mg, insulin degludec, and insulin glargine. This post hoc analysis assessed the effect of tirzepatide use on the prevalence of patients meeting the criteria for metabolic syndrome across SURPASS 1–5.MethodsMetabolic syndrome was defined as having ≥ 3 of 5 criteria according to the US National Cholesterol Education Program: Adult Treatment Panel III. Analyses were based on on-treatment data at the primary endpoint from patients adherent to treatment (taking ≥ 75% study drug). A logistic regression model with metabolic syndrome status as the response variable, metabolic syndrome status at the baseline visit as an adjustment, and randomized treatment as fixed explanatory effect was used. The effect of tirzepatide use on the prevalence of patients meeting the criteria for metabolic syndrome by categorical weight loss, background medication and gender were assessed.ResultsIn SURPASS, the prevalence of patients meeting the criteria for metabolic syndrome at baseline was 67–88% across treatment groups with reductions at the primary endpoint to 38–64% with tirzepatide versus 64–82% with comparators. Reductions in the prevalence of patients meeting the criteria for metabolic syndrome was significantly greater with all tirzepatide doses versus placebo, semaglutide 1 mg, insulin glargine, and insulin degludec (p < 0.001). Individual components of metabolic syndrome were also reduced to a greater extent with tirzepatide vs comparators. Greater reductions in body weight were associated with greater reductions in the prevalence of patients meeting the criteria for metabolic syndrome and its individual components. Background SGLT2i or sulfonylurea use or gender did not impact the change in prevalence of patients meeting the criteria for metabolic syndrome.ConclusionsIn this post hoc analysis, tirzepatide at all doses studied was associated with a greater reduction in the prevalence of patients meeting the criteria for metabolic syndrome compared to placebo, semaglutide 1 mg, insulin degludec, and insulin glargine. Although more evidence is needed, these data would support greater potential improvement in cardiovascular risk factor profile with tirzepatide treatment in people across the continuum of T2D.

Cognitive Performance in Individuals With Changes in Metabolic Syndrome Status in the Lifelines Cohort Study

Cognitive Performance in Individuals With Changes in Metabolic Syndrome Status in the Lifelines Cohort Study

Association between Metabolic Syndrome and Musculoskeletal Status: A Cross-Sectional Study of NHANES.

The metabolic effects of metabolic syndrome (MetS) on musculoskeletal metabolism are controversial. This study explored the effect of MetS on bone mineral density (BMD) and muscle quality index (MQI). Data from the NHANES database from 2011 to 2014 were extracted, and nonpregnant participants aged 45-59 years were included. The included data were first weighted by complex sampling, and then, the effect of MetS on BMD and MQI was analyzed using multifactorial linear regression. We then performed a stratified analysis by gender and BMI classification. Moreover, a mediation analysis of MetS on BMD was conducted, with MQI as a mediating variable. A propensity score matching analysis method with a complex sampling design was additionally performed to verify the stability of the results. A total of 1943 participants were eventually included. After adjusting for covariates, the results of linear regression show that MetS is associated with elevated pelvic BMD (beta = 0.03; 95% CI = 0.01, 0.06; P=0.02) and reduced MQI, especially arm MQI (beta = -1.02; 95% CI = -1.27, -0.77; P < 0.0001). MetS is more associated with BMD in women, MQI in normal or heavyweight, and BMD in lightweight, according to stratified analysis. MQI explains the indirect effect of MetS on BMD (beta = 0.007; 95% CI = 0.003, 0.010). This study provides evidence that MetS elevates BMD and reduces MQI, and further, that there is a mediating effect of MQI on elevated BMD.

Cost-Effectiveness Analysis of Rabies Control Program, 2008–2017: A Systematic Review

Rabies is still a public health problem. It is a zoonotic disease caused by a viral infection of the central nervous system. Several efforts have been taken, and one of them is mass vaccination for dogs. This systematic review aims to assess the cost-effectiveness of controlling rabies disease. Three online databases used as the source of this review are PubMed, ProQuest and CINAHL (EBSCO), published between 2008 and 2017. Fourteen articles reviewed based on the eligibility criteria were related to the intervention in preventing and controlling rabies. The articles consist of three randomised controlled trials and six nonrandomised controlled trials, including a pre-test-post-test-controlled design. Moreover, there is a one-time series article, which is an intervention for only one group of samples. Eight articles are directed at the intervention of lifestyles involving increased physical activity, diet and nutrition, with the main purpose to prevent the increase of metabolic syndrome status. Cost-effectiveness estimation is based on the mass vaccination programme for dogs, post-exposure prophylaxis (PEP) administration for humans and the combination of both. The model and variables in cost-effectiveness analysis are widely varied and associated with demography, socio-economics and programmes conducted in the study area.

Modification of incident cancer risk with changes in metabolic syndrome status: A prospective cohort study in Taiwan

PurposeWe aimed to investigate the effect of altered metabolic syndrome (MetS) status on cancer risk. MethodsFrom 2002 through 2008 of the Taiwan MJ cohort, there were 111,616 adults who had repeated MetS measurements performed 3.3 years apart and were followed up for cancer incidence over 11.8 years. Cancer was confirmed based on histopathological reports. ResultsParticipants were categorized as MetS-free (n = 80,409; no MetS at the first or last health screening), MetS-developed (n = 9833; MetS absence at the first screening and presence at the last screening), MetS-recovered (n = 8958; MetS presence at the first screening and absence at the last screening), and MetS-persisted (n = 12,416; MetS presence at the first and last screenings). We used the Fine-Gray sub-distribution method, with death as competing risk, to determine the association between MetS changes and incident cancer risk. During 1320,796 person-years of follow-up, 5862 individuals developed cancer. The incidence rate of cancer per 1000 person-years was 3.89 in the MetS-free, 5.26 in MetS-developed, 4.61 in MetS-recovered, and 7.33 in MetS-persisted groups (P < .001). Compared with the MetS-free group, MetS-persisted individuals had a higher risk of incident cancer. ConclusionsPersistent MetS was found to be associated with a high risk of incident cancer.

Prognostic value of coronary computed tomography angiography parameters, non-alcoholic fatty liver and metabolic syndrome status in symptomatic patients suspected of coronary artery disease

Abstract Background Metabolic syndrome (MetS) is a well-established risk factor for major adverse cardiovascular events (MACE). Previous studies have shown the relationship between MetS, computed tomography derived epicardial fat volume (EFV), non-alcoholic fatty liver disease (NAFLD) status and coronary artery calcium score (CACS) in asymptomatic patients. Objective To assess the prognostic value of coronary computed tomography angiography (CCTA) derived EFV, NAFLD status, CACS and the number of plaques (NoP) in symptomatic patients with and without MetS and to design a new risk score for predicting MACE. Methods We conducted a single-centre, cross-sectional study on 2038 patients with intermediate risk of CAD, which underwent CCTA between March 2019 and May 2022. Data regarding MetS status and other comorbidities were assessed at the moment of the inclusion in the study. CCTA assessment included: CACS, NoP, EFV and NAFLD status. The endpoint was the occurrence of MACE (late revascularization, myocardial infarction, sudden cardiac death). Cox regression was used to assess the relationship between MetS and CCTA derived variables on the occurrence of MACE. Receiver operating characteristic curve analysis was used to determine the prediction value of CCTA derived parameters and of the new risk score. Net reclassification improvement was used to compare the risk score with CACS ability to predict MACE. Results Patients were prospectively followed up during a mean time of 26.9 (standard deviation: 9.5) months. 361 (17.7%) patients developed a MACE (myocardial infarction, n=67; late revascularization, n=282; sudden cardiac death, n=12). More events were seen in MetS+ patients (n=244) versus MetS- patients (n=117) (p&amp;lt;0.001). MetS, age, male gender, CACS, NoP, EFV and NAFLD were all associated with the occurrence of MACE: unadjusted hazard ratios (HR) of: 1.56, 1.25, 1.87, 1.0013, 1.16, 1.053 and 1.67 (p&amp;lt;0.001 for all). However, in the multivariate analysis only the CCTA derived variables showed a significant association with MACE: CCS HR=1.001, NoP HR=1.097, EFV HR=1.035, NAFLD HR=1.843 (p&amp;lt;0.001 for all). Our risk score for predicting MACE included CACS, NoP, EFV and NAFLD. It had an area under the curve (AUC) of 0.948, a sensitivity of 89.7%, a specificity of 92.9% and a negative predicting value of 97.7%. When compared to CCS alone, the risk score correctly reclassified 24 (6.6%) events and 101 (6.2%) non-events, with a net reclassification index of 0.128 (p&amp;lt;0.001). Conclusion MetS is associated with an increased risk for MACE, but not after adjustment for CCS, NoP, EFV, and NAFLD. Adding NoP, EFV and NAFLD to CCS in a risk score further improves the accuracy in predicting MACE, when compared to CCS alone.

Prevalence of metabolic syndrome and improper nutritional status among adolescents.

Prevalence of metabolic syndrome (MetS) and its components is a growing issue, including pediatric populations. However, because of many definitions used, it is difficult to assess the true frequency of these problems. The aim of this study was to assess the prevalence of MetS and its components as well as the frequency of problems with inadequate nutritional status among adolescents. One hundred ninety-six teenagers aged 15-18 years, living in Krakow and its vicinity were examined including measurement of blood pressure, anthropometric parameters and blood levels of cholesterol and glucose. The prevalence of MetS was low and varied from 0.5% to 2.0% depending on the definition. Based on Cook's definition of MetS, the most common components were hypertension (12.8%) and hypertriglyceridemia (12.8%). Improper body weight (based on BMI) was found in 23.5% of adolescents, including 5.1% underweight, and 18.4% overweight or obese. According to the body fat percentage (BF%), 45.8% of the boys were underfat and 6.3% had too much body fat, while only 4% of the girls were below the BF% reference values and 15% above. All girls and 86.5% of boys had too low total body water. In conclusion, the prevalence of metabolic syndrome in population of Krakow adolescents was relatively low, but more than 12% of the adolescents had a hypertension or hypertriglyceridemia. Based on BMI most of adolescents were found to have adequate body weight, but examination of fat content in the body high prevalence of underfat was observed, especially among boys.

Burden, determinants and treatment status of metabolic syndrome among older adults in India: a nationally representative, community-based cross-sectional survey

IntroductionMetabolic syndrome is a significance driver of mortality and morbidity in India, but nationally representative data regarding disease burden and treatment status are lacking. Here, a cross-sectional study was undertaken...

The association of metabolic syndrome status with sensorineural hearing loss in pediatric obese patients

The association of metabolic syndrome status with sensorineural hearing loss in pediatric obese patients

Link Between Obesity and Periodontitis Severity: A Population-Based Study

Obesity contributes to an overall inflammatory condition through its metabolic and immune parameters, therebyincreasing susceptibility to periodontal disease and periodontitis being one of the most common chronic inflammatory diseases.Therefore, by evaluating the risk variables for Obesity and periodontitis, we could know the association, influence, and severityof Periodontal disease. 150 individuals reported to the Department of Periodontics, SBDCH, who were more than 35-70 yearsof age with mild, moderate, and severe Periodontitis were included in the study. A clinical examination was performed, whichincluded height, weight, waist circumference, abdominal/hip circumference, and blood pressure. On Intra oral examination,bleeding on probing, Periodontal probing pocket depth, and clinical attachment level was measured to assess the severity of theperiodontal condition. In addition, a blood investigation of lipid profile and HbA1C was taken. We found a statistically significantassociation between metabolic syndrome and Periodontal status. Obesity influences the severity of Periodontitis, and it's apopulation-based cross-sectional study; all the independent risk variables have a major role in developing the risk ofperiodontitis. Periodontitis has been proposed to contribute to systemic conditions such as cardiovascular disease primarilythrough the inflammatory and microbial burden posed by the inflamed surface area of the periodontal pocket.

Association Between Sleep Duration and Stroke in Different Status of Metabolic Syndrome: A Cross-Sectional Study in Shanghai Adult Residents.

This study aimed to investigate the relationship between sleep duration (SD) and stroke, and examine the effects of SD on stroke with or without metabolic syndrome (Mets) and its components among the adult residents in Shanghai, China. A total of 20,245 participants (51.72% male, mean age 44.66 years) were included from Shanghai Chronic Disease and Risk Factors Surveillance (SCDRFS) in 2017. The weighted logistic regressions were performed to examine the associations between SD and stroke in different status of Mets and its components. The mean SD was 7.51±0.03 h/d. After adjusting for all the potential factors, SD<6 h/d (OR=1.73, 95% CI: 1.35-2.20) or ≥10 h/d (OR=1.66, 95% CI: 1.08-2.57) was significantly positively associated with stoke in the total participants; moreover, in the non-Mets group, only SD<6 h/d (OR=1.77, 95% CI: 1.19, 2.64) significantly increased the risk of stroke; while, in the Mets group, SD<6 h/d (OR=1.80, 95% CI:1.17-2.76) and ≥10 h/d (OR=1.97, 95% CI: 1.00-3.88) both had a positive significantly association with stoke. In addition, the effects of SD<6 h/d on stroke were more pronounced among those with high WC (OR=2.24, 95% CI: 1.40-3.58) and high TG (OR=2.60, 95% CI: 1.86-3.62), and the effects of SD≥10 h/d on stroke were more evident among those with high TG (OR=2.28, 95% CI: 1.02-5.08) and high FBG (OR=2.58, 95% CI: 1.30-5.10). Both short and long SD were significantly positively associated with stroke in the total participants, and the associations were stronger in the Mets group; conversely, in the non-Mets group, only short SD was significantly positively associated with stroke, and no significant association was observed between long SD and stroke. Therefore, more precise sleep measures may be needed to prevent stroke according to the different status of Mets.